Geron Co. has a 12-month low of $1.64 and a 12-month high of $5.34. The company has a market capitalization of $1.77 billion, a P/E ratio of -9.16 and a beta of 0.53.

Geron is also testing the drug for myelofibrosis (MF), another form of bone marrow cancer, and expects data from the phase 3 IMpactMF trial of imetelstat in relapsed/refractory MF in 2024.

Many people today deny the reality of original sin. Modern thinkers claim that evolution disproves it. Some object to the idea of inheriting sin from our parents, while others simply deny sin itself.

Geron's first-in-class cancer drug Rytelo, recently approved by the FDA for myelodysplastic syndromes (MDS), is priced three to four times higher than it should be, according to the Institute for ...

13 Februari 2025 11 Februari 2025 oleh Wadiyo, S.E. Contoh Laporan Keuangan Sederhana Toko Baju/Distro (fashion) beserta tutorial sederhana membuat laporan tersebut. Tutorial ini akan menunjukkan ...

After hours: 7:44:05 p.m. EST ...

We currently have no GERN Stock Split History on this stock.

Max has had quite a journey from its original launch as HBO Max to the now combined library featuring former Discovery+ series alongside HBO hits. But within the existing IPs and unscripted ...